Get started
Author

Richard Hippensteel

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment
1999 · Jeffrey M. Drazen, Chandri N. Yandava, et al. · Nature Genetics · 556
Antiproteinuric effect of oral paricalcitol in chronic kidney disease
2005 · Rajiv Agarwal, Muralidhar Acharya, et al. · Kidney International · 374
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis
2007 · Edward A. Ross, Jin Tian, et al. · American Journal of Nephrology · 61
A Comparison of Dosing Regimens of Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in CKD Stages 3 and 4
2006 · Hanna Abboud, Daniel Coyne, et al. · American Journal of Nephrology · 26
Erratum
2007 · Theodoros Eleftheriadis, Charalambos Kartsios, et al. · American Journal of Nephrology
PDF
217
2007 · Stuart Sprague, Joel Melnick, et al. · American Journal of Kidney Diseases
A Phase 2 Study of the Thrombospondin-Mimetic Peptide ABT-510 in Patients with Refractory Lymphoma.
2005 · Alexandra M. Levine, Lee Schwartzberg, et al. · Blood
Relationship between genotype at the 5-lipoxygenase core promoter locus and the clinical response to ABT-761
1999 · Drazen Jeffrey, Chandri Yandava, et al. · Prostaglandins & Other Lipid Mediators
Works count: 8
Citation count: 1,016
H-index: 4
I10-index: 4
Year
Topic
Type